Take Solutions Ltd
Incorporated in 2000, TAKE Solutions Ltd is in the business of Life Sciences and Support Services[1]
- Market Cap ₹ 254 Cr.
- Current Price ₹ 17.2
- High / Low ₹ 35.8 / 16.3
- Stock P/E
- Book Value ₹ -0.60
- Dividend Yield 0.00 %
- ROCE -20.9 %
- ROE -52.5 %
- Face Value ₹ 1.00
Pros
- Company has reduced debt.
Cons
- Company has low interest coverage ratio.
- The company has delivered a poor sales growth of -49.7% over past five years.
- Company has a low return on equity of -106% over last 3 years.
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Sector: Miscellaneous Industry: Miscellaneous
Quarterly Results
Consolidated Figures in Rs. Crores / View Standalone
Profit & Loss
Consolidated Figures in Rs. Crores / View Standalone
Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
832 | 816 | 730 | 1,030 | 1,345 | 1,587 | 2,039 | 2,213 | 774 | 655 | 189 | 66 | |
670 | 668 | 581 | 817 | 1,082 | 1,281 | 1,655 | 2,044 | 847 | 648 | 208 | 78 | |
Operating Profit | 161 | 147 | 149 | 213 | 262 | 307 | 384 | 169 | -73 | 7 | -19 | -13 |
OPM % | 19% | 18% | 20% | 21% | 20% | 19% | 19% | 8% | -9% | 1% | -10% | -20% |
7 | 6 | 8 | 21 | 13 | 6 | 11 | 26 | -211 | -677 | -56 | -92 | |
Interest | 14 | 14 | 13 | 15 | 23 | 21 | 25 | 41 | 37 | 29 | 7 | 5 |
Depreciation | 46 | 77 | 60 | 74 | 87 | 104 | 154 | 167 | 115 | 80 | 17 | 8 |
Profit before tax | 107 | 63 | 85 | 145 | 165 | 188 | 216 | -13 | -437 | -779 | -99 | -118 |
Tax % | 17% | 2% | 6% | 14% | 11% | 15% | 17% | -15% | 3% | 0% | 2% | 1% |
89 | 62 | 80 | 125 | 146 | 160 | 178 | -11 | -450 | -782 | -100 | -120 | |
EPS in Rs | 6.49 | 4.74 | 5.71 | 9.78 | 10.74 | 10.85 | 11.99 | -0.84 | -30.56 | -52.88 | -6.78 | -8.09 |
Dividend Payout % | 15% | 21% | 17% | 10% | 9% | 15% | 8% | 0% | 0% | 0% | 0% | 0% |
Compounded Sales Growth | |
---|---|
10 Years: | -22% |
5 Years: | -50% |
3 Years: | -56% |
TTM: | -65% |
Compounded Profit Growth | |
---|---|
10 Years: | % |
5 Years: | % |
3 Years: | 24% |
TTM: | 71% |
Stock Price CAGR | |
---|---|
10 Years: | -11% |
5 Years: | -29% |
3 Years: | -30% |
1 Year: | -23% |
Return on Equity | |
---|---|
10 Years: | -6% |
5 Years: | -31% |
3 Years: | -106% |
Last Year: | -52% |
Balance Sheet
Consolidated Figures in Rs. Crores / View Standalone
Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Equity Capital | 12 | 12 | 12 | 12 | 13 | 15 | 15 | 15 | 15 | 15 | 15 | 15 |
Reserves | 408 | 458 | 512 | 619 | 898 | 1,314 | 1,504 | 1,561 | 1,110 | 166 | 94 | -24 |
196 | 207 | 209 | 336 | 237 | 323 | 474 | 553 | 514 | 59 | 46 | 37 | |
220 | 185 | 189 | 246 | 221 | 189 | 339 | 336 | 187 | 984 | 69 | 60 | |
Total Liabilities | 837 | 862 | 922 | 1,214 | 1,369 | 1,840 | 2,331 | 2,465 | 1,826 | 1,223 | 224 | 88 |
368 | 384 | 359 | 543 | 554 | 589 | 1,091 | 1,234 | 934 | 101 | 73 | 30 | |
CWIP | 3 | 2 | 17 | 3 | 21 | 42 | 41 | 1 | 0 | 3 | 11 | 0 |
Investments | 50 | 50 | 6 | 21 | 10 | 59 | 10 | 18 | 7 | 0 | 0 | 0 |
415 | 426 | 541 | 647 | 785 | 1,150 | 1,188 | 1,213 | 885 | 1,119 | 140 | 58 | |
Total Assets | 837 | 862 | 922 | 1,214 | 1,369 | 1,840 | 2,331 | 2,465 | 1,826 | 1,223 | 224 | 88 |
Cash Flows
Consolidated Figures in Rs. Crores / View Standalone
Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
117 | 100 | 74 | 151 | 56 | 121 | 104 | 211 | 135 | 30 | 20 | 9 | |
-70 | -91 | -14 | -292 | -130 | -179 | -474 | -233 | -57 | 15 | -3 | -7 | |
-31 | -7 | -11 | 111 | 56 | 302 | 100 | 21 | -84 | -55 | -36 | -12 | |
Net Cash Flow | 16 | 2 | 49 | -30 | -18 | 243 | -270 | -2 | -6 | -10 | -18 | -10 |
Ratios
Consolidated Figures in Rs. Crores / View Standalone
Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Debtor Days | 99 | 100 | 120 | 107 | 118 | 108 | 94 | 116 | 205 | 45 | 58 | 39 |
Inventory Days | ||||||||||||
Days Payable | ||||||||||||
Cash Conversion Cycle | 99 | 100 | 120 | 107 | 118 | 108 | 94 | 116 | 205 | 45 | 58 | 39 |
Working Capital Days | 71 | 83 | 121 | 107 | 136 | 143 | 142 | 137 | 289 | 45 | 20 | -135 |
ROCE % | 20% | 11% | 13% | 16% | 17% | 15% | 13% | 1% | -9% | -6% | -14% | -21% |
Documents
Announcements
-
Delay In Submission Of Financial Results Under Regulation 33 Of SEBI (LODR) Regulations, 2015 ('LODR'), For The Quarter Ended September 30, 2024
2 Dec - Delay in submission of Q2 financial results.
-
Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018
14 Oct - Certificate under Regulation 74(5) of SEBI (Depositories and Participants) Regulation, 2018 for the quarter ended September 30, 2024.
-
Shareholder Meeting / Postal Ballot-Scrutinizer"s Report
11 Oct - Voting results of Extra-Ordinary General Meeting disclosed.
- Shareholder Meeting / Postal Ballot-Outcome of EGM 9 Oct
- Announcement under Regulation 30 (LODR)-Newspaper Publication 5 Oct
Annual reports
-
Financial Year 2024
from bse
-
Financial Year 2023
from bse
-
Financial Year 2022
from bse
-
Financial Year 2021
from bse
-
Financial Year 2020
from bse
-
Financial Year 2019
from bse
-
Financial Year 2018
from bse
-
Financial Year 2017
from bse
-
Financial Year 2016
from bse
-
Financial Year 2015
from bse
-
Financial Year 2014
from bse
-
Financial Year 2013
from bse
-
Financial Year 2012
from bse
-
Financial Year 2011
from bse
-
Financial Year 2010
from nse
Concalls
-
Aug 2021TranscriptPPT
-
Jun 2021TranscriptPPT
-
Feb 2021TranscriptPPT
-
Dec 2020TranscriptPPT
-
Sep 2020TranscriptPPT
-
Oct 2019TranscriptPPT
-
Aug 2019TranscriptPPT
-
May 2019TranscriptPPT
-
Mar 2019TranscriptPPT
-
Feb 2019TranscriptPPT
-
Feb 2019TranscriptPPT
-
Aug 2018TranscriptPPT
-
May 2018TranscriptPPT
-
Feb 2018TranscriptPPT
-
Nov 2017TranscriptPPT
-
Nov 2017TranscriptPPT
-
Aug 2017TranscriptPPT
-
May 2017TranscriptPPT
-
Jan 2017TranscriptPPT
-
Dec 2016TranscriptPPT
-
Oct 2016TranscriptPPT
-
Feb 2016TranscriptNotesPPT
Business Overview:[1]
Singapore-based TAKE Solutions Pte Limited holds a 52.90% stake in TSL, serving as the holding company. TSL specializes in Life Sciences and Supply Chain Management, providing comprehensive services in clinical development and specific offerings in supply chain. The company is involved in clinical trials, generics support, including bio-availability & bioequivalent studies, regulatory filing, and pharmacovigilance.